Clinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies

International Journal of Clinical Rheumatology

Volumn 5, Issue 5, 2010, Pages 523-536

  Nakashima, Ran ^a   Mimori, Tsuneyo ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

amyopathic dermatomyositis; idiopathic inflammatory myopathy; malignancy associated myositis; myositis specific autoantibody; necrotizing myopathy

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CADM 140 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; KU ANTIBODY; METHOTREXATE; MI 2 ANTIBODY; PM SCL ANTIBODY; PROTEIN 200/100 ANTIBODY; PROTEIN NXP 2 ANTIBODY; PROTEIN P155 ANTIBODY; RITUXIMAB; RO ANTIBODY; SIGNAL RECOGNITION PARTICLE ANTIBODY; SMALL UBIQUITIN LIKE MODIFIER ACTIVATING ENZYME ANTIBODY; TACROLIMUS; U1 RNP ANTIBODY; UNCLASSIFIED DRUG;

AMYOPATHIC DERMATOMYOSITIS; ANTIBODY DETECTION; ANTISYNTHETASE SYNDROME; CLINICAL FEATURE; DERMATOMYOSITIS; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; HUMAN; IDIOPATHIC INFLAMMATORY MYOPATHY; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; MALIGNANCY ASSOCIATED MYOSITIS; MYOPATHY; MYOSITIS; PATHOGENESIS; PATHOPHYSIOLOGY; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 77958029240     PISSN: 17584272     EISSN: None     Source Type: Journal    
DOI: 10.2217/ijr.10.48     Document Type: Review

References (95)

1. Yoshifuji H, Fujii T, Kobayashi S et al.: Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 39(3), 233-241 (2006).
2. Nishikai M, Reichlin M: Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum. 23(8), 881-888 (1980).
3. Mathews MB, Bernstein RM: Myositis autoantibody inhibits histidyl-tRNA synthetase: A model for autoimmunity. Nature 304(5922), 177-179 (1983).
4. Mathews MB, Reichlin M, Hughes GR, Bernstein RM: Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J. Exp. Med. 160(2), 420-434 (1984).
5. Targoff IN, Arnett FC, Reichlin M: Antibody to threonyl-transfer RNA synthetase in myositis sera. Arthritis Rheum. 31(4), 515-524 (1988).
6. Bunn CC, Bernstein RM, Mathews MB: Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J. Exp. Med. 163(5), 1281-1291 (1986).
7. Targoff IN, Arnett FC: Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am. J. Med. 88(3), 241-251 (1990).
8. Targoff IN, Trieu EP, Plotz PH, Miller FW: Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum. 35(7), 821-830 (1992).
9. Targoff IN, Trieu EP, Miller FW: Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J. Clin. Invest. 91(6), 2556-2564 (1993).
10. Hirakata M, Suwa A, Nagai S et al.: Anti-KS: Identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J. Immunol. 162(4), 2315-2320 (1999).
11. Targoff IN: Immune manifestations of inflammatory muscle disease. Rheum. Dis. Clin. North Am. 20(4), 857-880 (1994).
12. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N: Anti-synthetase syndrome: A new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 46(6), 1005-1008 (2007).
13. Hashish L, Trieu EP, Sadanandan P, Targoff IN: Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome. Arthritis Rheum. 52(Suppl. 9), S312 (2005).
14. Schnabel A, Reuter M, Gross WL: Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum. 41(7), 1215-1220 (1998).
15. Maeda K, Kimura R, Komuta K, Igarashi T: Cyclosporine treatment for polymyositis/dermatomyositis: Is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand. J. Rheumatol. 26(1), 24-29 (1997).
16. Nawata Y, Kurasawa K, Takabayashi K et al.: Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: Prediction and treatment with cyclosporine. J. Rheumatol. 26(7), 1527-1533 (1999).
17. Hengstman GJ, van den Hoogen FH, van Engelen BG: Treatment of the inflammatory myopathies: Update and practical recommendations. Expert Opin. Pharmacother. 10(7), 1183-1190 (2009).
18. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV: Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 52(8), 2439-2446 (2005).
19. Sato S, Hirakata M, Kuwana M et al.: Clinical characteristics of Japanese patients with anti-PL-7 (anti-threonyl-tRNA synthetase) autoantibodies. Clin. Exp. Rheumatol. 23(5), 609-615 (2005). (Pubitemid 41300701)
20. Yamasaki Y, Yamada H, Nozaki T et al.: Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum. 54(6), 2004-2009 (2006).
21. Hirakata M, Suwa A, Takada T et al.: Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum. 56(4), 1295-1303 (2007).
22. Kalluri M, Sahn SA, Oddis CV et al.: Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 135(6), 1550-1556 (2009).
23. Sato S, Kuwana M, Hirakata M: Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies. Rheumatology (Oxford) 46(5), 842-845 (2007). (Pubitemid 47061719)
24. Howard OM, Dong HF, Yang D et al.: Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J. Exp. Med. 196(6), 781-791 (2002).
25. Wakasugi K, Schimmel P: Highly differentiated motifs responsible for two cytokine activities of a split human tRNA synthetase. J. Biol. Chem. 274(33), 23155-23159 (1999).
26. Wakasugi K, Schimmel P: Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science 284(5411), 147-151 (1999).
27. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A: Cleavage by granzyme B is strongly predictive of autoantigen status: Implications for initiation of autoimmunity. J. Exp. Med. 190(6), 815-826 (1999).
28. Levine SM, Rosen A, Casciola-Rosen LA: Anti-aminoacyl tRNA synthetase immune responses: Insights into the pathogenesis of the idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 15(6), 708-713 (2003).
29. Reeves WH, Nigam SK, Blobel G: Human autoantibodies reactive with the signal-recognition particle. Proc. Natl Acad. Sci. USA 83(24), 9507-9511 (1986).
30. Okada N, Mimori T, Mukai R, Kashiwagi H, Hardin JA: Characterization of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle. J. Immunol. 138(10), 3219-3223 (1987).
31. Targoff IN, Johnson AE, Miller FW: Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 33(9), 1361-1370 (1990).
32. Hirakata M, Mimori T, Akizuki M, Craft J, Hardin JA, Homma M: Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum. 35(4), 449-456 (1992).
33. Satoh T, Okano T, Matsui T et al.: Novel autoantibodies against 7SL RNA in patients with polymyositis/dermatomyositis. J. Rheumatol. 32(9), 1727-1733 (2005).
34. Hengstman GJ, ter Laak HJ, Vree Egberts WT et al.: Anti-signal recognition particle autoantibodies: Marker of a necrotising myopathy. Ann. Rheum. Dis. 65(12), 1635-1638 (2006).
35. Miller T, Al-Lozi MT, Lopate G, Pestronk A: Myopathy with antibodies to the signal recognition particle: Clinical and pathological features. J. Neurol. Neurosurg. Psychiatry 73(4), 420-428 (2002).
36. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV: Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 50(1), 209-215 (2004).
37. Arlet JB, Dimitri D, Pagnoux C et al.: Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul. Disord. 16(5), 334-336 (2006).
38. Whelan BR, Isenberg DA: Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology (Oxford) 48(5), 594-595 (2009).
39. Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L: Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: A case series. Arthritis Care Res. (Hoboken) (2010) (Epub ahead of print).
40. Targoff IN, Reichlin M: The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 28(7), 796-803 (1985).
41. Rider LG, Miller FW, Targoff IN et al.: A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum. 37(10), 1534-1538 (1994).
42. Seelig HP, Moosbrugger I, Ehrfeld H, Fink T, Renz M, Genth E: The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum. 38(10), 1389-1399 (1995).
43. Ge Q, Nilasena DS, O'Brien CA, Frank MB, Targoff IN: Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen. J. Clin. Invest. 96(4), 1730-1737 (1995).
44. Seelig HP, Renz M, Targoff IN, Ge Q, Frank MB: Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen. Arthritis Rheum. 39(10), 1769-1771 (1996).
45. Komura K, Fujimoto M, Matsushita T et al.: Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. J. Dermatol. Sci. 40(3), 215-217 (2005).
46. Hengstman GJ, Vree Egberts WT, Seelig HP et al.: Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2b antigen. Ann. Rheum. Dis. 65(2), 242-245 (2006).
47. Love LA, Weinberg CR, McConnaughey DR et al.: Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum. 60(8), 2499-2504 (2009).
48. Euwer RL, Sontheimer RD: Amyopathic dermatomyositis: A review. J. Invest. Dermatol. 100(1), 124S-127S (1993).
49. Ye S, Chen XX, Lu XY et al.: Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: A retrospective cohort study. Clin. Rheumatol. 26(10), 1647-1654 (2007).
50. Suda T, Fujisawa T, Enomoto N et al.: Interstitial lung diseases associated with amyopathic dermatomyositis. Eur. Respir. J. 28(5), 1005-1012 (2006).
51. Sato S, Hirakata M, Kuwana M et al.: Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 52(5), 1571-1576 (2005).
52. Nakashima R, Imura Y, Kobayashi S et al.: The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49(3), 433-440 (2010).
53. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M: RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 60(7), 2193-2200 (2009).
54. Christensen ML, Pachman LM, Schneiderman R, Patel DC, Friedman JM: Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum. 29(11), 1365-1370 (1986).
55. Chevrel G, Calvet A, Belin V, Miossec P: Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle. Rheumatology (Oxford) 39(9), 1037-1039 (2000).
56. Bowles NE, Dubowitz V, Sewry CA, Archard LC: Dermatomyositis, polymyositis, and Coxsackie-B-virus infection. Lancet 1(8540), 1004-1007 (1987).
57. Targoff IN, Mamyrova G, Trieu EP et al.: A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 54(11), 3682-3689 (2006).
58. Kaji K, Fujimoto M, Hasegawa M et al.: Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: An association with malignancy. Rheumatology (Oxford) 46(1), 25-28 (2007).
59. Targoff IN, Levy-Neto M, Prasertsuntarasai T, Miller FW: Autoantibodies to transcriptional intermediary factor 1-g (TIF1-g) in dermatomyositis [abstract]. Arthritis Rheum. 54, S518 (2006).
60. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T: Anti-MDA5 and anti-TIF1-?antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 49(9), 1726-1733 (2010).
61. Genth E, Mierau R, Genetzky P et al.: Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum. 33(5), 657-665 (1990).
62. Kuwana M, Okano Y, Kaburaki J, Tojo T, Medsger TA Jr: Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum. 37(6), 902-906 (1994). (Pubitemid 24184543)
63. Gunawardena H, Wedderburn LR, Chinoy H et al.: Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 60(6), 1807-1814 (2009).
64. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV: Clinical and serologic characterization of an Argentine pediatric myositis cohort: Identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J. Rheumatol. 36(11), 2547-2551 (2009).
65. Betteridge ZE, Gunawardena H, Chinoy H et al.: Autoantibodies to the p140 autoantigen NXP-2 in adult dermatomyositis. Arthritis Rheum. 60, S304 (2009).
66. Betteridge ZE, Gunawardena H, Chinoy H et al.: Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann. Rheum. Dis. 68(10), 1621-1625 (2009).
67. Christopher-Stine L, Hong G, Casciola-Rosen L, Corse AM, Mammen AL: A novel autoantibody against 200/100 kd proteins is associated with necrotizing myopathy. Arthritis Rheum. 60, S430 (2009).
68. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR: Mixed connective tissue disease - an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am. J. Med. 52(2), 148-159 (1972).
69. van Venrooij WJ, Hoet R, Castrop J, Hageman B, Mattaj IW, van de Putte LB: Anti-(U1) small nuclear RNA antibodies in anti-small nuclear ribonucleoprotein sera from patients with connective tissue diseases. J. Clin. Invest. 86(6), 2154-2160 (1990).
70. Kallenberg CG: Overlapping syndromes, undifferentiated connective tissue disease, and other fibrosing conditions. Curr. Opin. Rheumatol. 5(6), 809-815 (1993).
71. Kallenberg CG: Overlapping syndromes, undifferentiated connective tissue disease, and other fibrosing conditions. Curr. Opin. Rheumatol. 7(6), 568-573 (1995).
72. Lundberg I, Nyman U, Pettersson I, Hedfors E: Clinical manifestations and anti-(U1)snRNP antibodies: A prospective study of 29 anti-RNP antibody positive patients. Br. J. Rheumatol. 31(12), 811-817 (1992).
73. Takeda Y, Wang GS, Wang RJ et al.: Enzyme-linked immunosorbent assay using isolated (U) small nuclear ribonucleoprotein polypeptides as antigens to investigate the clinical significance of autoantibodies to these polypeptides. Clin. Immunol. Immunopathol. 50(2), 213-230 (1989).
74. Ghirardello A, Zampieri S, Iaccarino L et al.: [Myositis specific and myositis associated autoantibodies in idiopathic inflammatory myopathies: A serologic study of 46 patients]. Reumatismo 57(1), 22-28 (2005).
75. Rutjes SA, Vree Egberts WT, Jongen P et al.: Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin. Exp. Immunol. 109(1), 32-40 (1997).
76. Schulte-Pelkum J, Fritzler M, Mahler M: Latest update on the Ro/SS-A autoantibody system. Autoimmun. Rev. 8(7), 632-637 (2009).
77. Brouwer R, Hengstman GJ, Vree Egberts W et al.: Autoantibody profiles in the sera of European patients with myositis. Ann. Rheum. Dis. 60(2), 116-123 (2001).
78. La Corte R, Lo Mo Naco A, Locaputo A, Dolzani F, Trotta F: In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 39(3), 249-253 (2006).
79. Váncsa A, Csipo I, Nemeth J, Devenyi K, Gergely L, Danko K: Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol. Int. 29(9), 989-994 (2009).
80. Mimori T, Akizuki M, Yamagata H, Inada S, Yoshida S, Homma M: Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J. Clin. Invest. 68(3), 611-620 (1981).
81. Yaneva M, Arnett FC: Antibodies against Ku protein in sera from patients with autoimmune diseases. Clin. Exp. Immunol. 76(3), 366-372 (1989).
82. Yamamoto AM, Amoura Z, Johannet C et al.: Quantitative radioligand assays using de novo-synthesized recombinant autoantigens in connective tissue diseases: New tools to approach the pathogenic significance of anti-RNP antibodies in rheumatic diseases. Arthritis Rheum. 43(3), 689-698 (2000).
83. Wang J, Satoh M, Kabir F et al.: Increased prevalence of autoantibodies to ku antigen in African American versus white patients with systemic lupus erythematosus. Arthritis Rheum. 44(10), 2367-2370 (2001).
84. Cooley HM, Melny BJ, Gleeson R, Greco T, Kay TW: Clinical and serological associations of anti-Ku antibody. J. Rheumatol. 26(3), 563-567 (1999).
85. Franceschini F, Cavazzana I, Generali D et al.: Anti-Ku antibodies in connective tissue diseases: Clinical and serological evaluation of 14 patients. J. Rheumatol. 29(7), 1393-1397 (2002).
86. Gottlieb TM, Jackson SP: The DNA-dependent protein kinase: Requirement for DNA ends and association with Ku antigen. Cell 72(1), 131-142 (1993).
87. Downs JA, Jackson SP: A means to a DNA end: The many roles of Ku. Nat. Rev. Mol. Cell Biol. 5, 367-378 (2004).
88. Marguerie C, Bunn CC, Copier J et al.: The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 71(6), 327-336 (1992).
89. Reichlin M, Maddison PJ, Targoff I et al.: Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J. Clin. Immunol. 4(1), 40-44 (1984).
90. Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Medsger TA Jr: Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum. 35(10), 1211-1217 (1992).
91. Jablonska S, Blaszczyk M: Scleroderma overlap syndromes. Adv. Exp. Med. Biol. 455, 85-92 (1999).
92. Reimer G, Rose KM, Scheer U, Tan EM: Autoantibody to RNA polymerase I in scleroderma sera. J. Clin. Invest. 79(1), 65-72 (1987).
93. Ho KT, Reveille JD: The clinical relevance of autoantibodies in scleroderma. Arthritis Res. Ther. 5(2), 80-93 (2003).
94. Lega JC, Cottin V, Fabien N, Thivolet-Bejui F, Cordier JF: Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl- tRNA synthetase autoantibodies: A similar condition? J. Rheumatol. 37(5), 1000-1009 (2010).
95. Mamyrova G, O'Hanlon TP, Monroe JB et al.: Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum. 54(12), 3979-3987 (2006).